DropGenie Raises $5 Million in Seed-Plus Round
The biotech startup plans to use the new funding to advance its digital microfluidics technology for laboratory automation.
Updated on Oct. 26, 2026 in Biotech
Live Poll
Do you support increased investment in biotech startups aiming to automate drug discovery processes?
Biotech startup DropGenie has secured $5 million USD, or approximately $7 million CAD, in a seed-plus financing round. The company plans to utilize these funds to further develop its digital microfluidics platform before a planned commercial launch.
Why it matters
DropGenie aims to lower research costs by using electrical signals to manipulate liquid droplets, requiring up to 100 times fewer cells and reagents than traditional methods. This efficiency could transform how automated laboratory workflows are executed in the industry.
DropGenie utilizes digital microfluidics technology to manipulate small liquid amounts on a chip using electrical signals. This platform uses up to 100 times fewer cells and less reagent than traditional methods.
The players
DropGenie
A biotech startup that develops digital microfluidics technology to automate laboratory research tasks.
Skeleton Key
The venture capital firm that acted as the lead investor for DropGenie's latest equity financing round.
The details
The round was led by Skeleton Key and included participation from the BDC Capital Thrive Fund, Merck Global Health Innovation Fund, CQDM, Real Ventures, and Anges Québec. With offices in Montréal and Boston, the 10-person startup has also formed research partnerships with major entities including AbbVie, UCB Pharma, Danaher, and Sartorius.
Timeline
2018: DropGenie was founded.
October 26, 2026: The company announced the closing of its seed-plus financing round.
Q2 2027: Commercial launch is scheduled for the automated lab workflow platform.
The Tech Race
This development mirrors the efficiency milestones reached following the 2013 application of CRISPR gene-editing technology. It marks a clear progression toward high-precision, miniaturized laboratory workflows that reduce dependency on manual, large-scale processing.
While the technology is currently oriented toward research partnerships, success could lead to significantly cheaper drug development and pharmaceutical research costs. Developers and lab personnel may eventually see improved workflow speeds as automated platforms replace traditional methods.
The takeaway
The move toward microfluidics suggests a broader industry shift toward maximizing research efficiency by minimizing resource consumption. Investors should track the 2027 launch as a key indicator of whether these efficiencies can be successfully scaled for broader commercial use.
What happens next
DropGenie is preparing for the commercial launch of its automated lab workflows, which is currently scheduled for the second quarter of 2027.
Further reading
For more on the current landscape of laboratory innovation, visit the Biotech section.
Live Poll
Do you support increased investment in biotech startups aiming to automate drug discovery processes?
